long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
Published 1 year ago • 90 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:16
long-term safety of momelotinib for myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
3:02
latest updates on momelotinib: safety, durability of response & survival benefit
-
3:19
first-line treatment selection in myelofibrosis
-
4:14
long-term safety and efficacy of sutimlimab for chronic itp
-
10:55
the cost-benefit review in regional anaesthesia (mafeitzeral mamat, rapm 2024)
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
1:28
indirect comparison of momelotinib vs pacritinib safety and anemia outcomes in myelofibrosis
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
2:28
long-term momelotinib exposure in jaki-naïve or previously jaki-treated myelofibrosis patients
-
0:46
safety of treating myelofibrosis with ruxolitinib – results from jump trial
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
4:25
update on momelotinib for myelofibrosis
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis